PepGen Faces Clinical Hold on Lead DM1 Program, Discontinues DMD Program, and Reports Dilutive $107.6M Offering
PEPG has more than doubled off its 52-week low of $0.88 on elevated volume (1.9× avg).
Summary
PepGen announced a partial clinical hold on its lead DM1 drug candidate, discontinued its DMD program, and completed a highly dilutive $107.6 million equity offering, alongside repricing executive stock options.
Key Events · Product Development and Regulatory · PEPG
-
Partial Clinical Hold on Lead DM1 Program
The FDA placed a partial clinical hold on the Phase 2 FREEDOM2 trial for PGN-EDODM1, citing concerns from previously submitted preclinical pharmacology and toxicology studies. This follows the recent unblinding of Phase 1 data which showed transient kidney biomarkers at higher doses.
-
Discontinuation of DMD Program
The company voluntarily discontinued the development of PGN-EDO51 for Duchenne muscular dystrophy (DMD) and wound down all related R&D activities in May 2025, after the CONNECT1 Phase 2 trial did not achieve target dystrophin levels.
-
Significant Dilutive Equity Offering
In September 2025, PepGen completed a public offering of 35,937,500 shares at $3.20 per share, raising net proceeds of $107.6 million. This follows a $86.3 million raise in February 2024 from an ATM program and another offering.
-
Executive Stock Option Repricing
On November 4, 2025, the board approved repricing 3,557,903 employee stock options with exercise prices ranging from $8.89-$17.91 down to $4.53 per share, resulting in $3.4 million in incremental stock-based compensation expense.
Analysis · PEPG · Life Sciences
PepGen Inc. is facing significant setbacks with a partial clinical hold on its lead drug candidate, PGN-EDODM1, for Myotonic Dystrophy Type 1 (DM1), due to preclinical concerns. This comes after the company already discontinued its PGN-EDO51 program for Duchenne Muscular Dystrophy (DMD) in May 2025 due to insufficient efficacy. To extend its operational runway into the second half of 2027, the company completed a highly dilutive public offering in September 2025, raising $107.6 million. Further compounding shareholder concerns, the board approved a repricing of over 3.5 million employee stock options to a significantly lower exercise price of $4.53, indicating efforts to re-incentivize employees amidst these challenges. These events collectively signal increased risk and uncertainty regarding PepGen's pipeline and financial stability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PEPG was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $0.88 to $7.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.